Form 4: Fairmount Funds Management Plans Significant Investment in Cogent Biosciences

Fairmount Funds Management LLC, a 10% owner and director of Cogent Biosciences, Inc., plans to acquire an additional 2.78 million shares of common stock for $9 per share in July 2025.

Summary

• Fairmount Funds Management LLC, identified as a 10% owner and director of Cogent Biosciences, Inc. (COGT), is the reporting entity.
• The filing details a planned acquisition of 2,777,777 shares of Cogent Biosciences common stock.
• The transaction is scheduled to occur on July 10, 2025.
• The purchase price for these shares is set at $9 per share.
• Following this transaction, Fairmount Healthcare Fund II LP will indirectly beneficially own a total of 9,003,418 shares.
• Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC possess voting and investment power over the securities held by Fairmount Healthcare Fund II LP.

Sentiment

Score: 9

Explanation: A significant planned purchase by a major insider (10% owner and director) at a fixed price indicates strong confidence in the company's valuation and future prospects, signaling a highly positive outlook.

Positives

• A significant planned insider purchase by a 10% owner and director signals strong confidence in Cogent Biosciences' future prospects and valuation.
• The acquisition of 2,777,777 shares at a fixed price of $9 per share represents a substantial financial commitment from a key stakeholder.

Future Outlook

The planned acquisition of a significant number of shares by a major shareholder and director suggests a positive outlook on the company's future performance and valuation by the reporting entity.

Management Comments

• Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
• The Reporting Person may be deemed a director by deputization of Issuer by virtue of the fact that Peter Harwin serves on the board of directors of Issuer and is also a Managing Member of Fairmount Funds Management LLC.

Industry Context

This insider transaction reflects a significant investment by a major fund in a biotechnology company, which can be interpreted as a vote of confidence in the company's strategic direction or pipeline development within the competitive biotech industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive signal due to insider confidence, which may lead to increased investor interest and potentially a positive impact on share price.
• Company: Expected inflow of capital (if a direct issuance) and strengthened relationship with a major institutional investor, potentially enhancing financial stability and strategic alignment.

Next Steps

• Completion of the planned acquisition of 2,777,777 shares on July 10, 2025.

Key Dates

Recommendation

Keywords

Cogent Biosciences, COGT, Fairmount Funds Management, Insider Transaction, Form 4, Stock Purchase, Director, 10% Owner, Equity Investment